Banco Bilbao Vizcaya Argentaria S.A. Buys 1,268 Shares of Insulet Corporation $PODD

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. raised its stake in Insulet Corporation by 43.1%, acquiring an additional 1,268 shares, bringing its total holdings to 4,207 shares worth $1,097,000.
• Wall Street analysts have a positive outlook on Insulet's stock, with 16 analysts rating it as a Buy and raising target prices to as high as $380.00.
• Insulet reported a significant earnings beat, with EPS of $1.17 surpassing expectations, and revenue of $649.10 million for the quarter, reflecting a 32.9% year-over-year growth.

Banco Bilbao Vizcaya Argentaria S.A. raised its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 43.1% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 4,207 shares of the medical instruments supplier's stock after purchasing an additional 1,268 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Insulet were worth $1,097,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Zions Bancorporation National Association UT bought a new stake in Insulet during the first quarter worth $26,000. Larson Financial Group LLC grew its stake in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares in the last quarter. SouthState Corp grew its stake in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Insulet in the fourth quarter valued at about $42,000. Finally, Ramirez Asset Management Inc. bought a new position in shares of Insulet during the first quarter valued at about $53,000.

Analysts Set New Price Targets

PODD has been the subject of a number of recent analyst reports. Canaccord Genuity Group upped their price objective on shares of Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Morgan Stanley reaffirmed an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Royal Bank Of Canada boosted their price objective on Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Barclays raised their target price on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $332.71.

Insulet Stock Performance

Shares of NASDAQ PODD traded up $2.63 during trading on Wednesday, reaching $334.46. 315,181 shares of the stock traded hands, compared to its average volume of 759,400. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The stock has a market capitalization of $23.54 billion, a P/E ratio of 101.62, a price-to-earnings-growth ratio of 2.76 and a beta of 1.35. Insulet Corporation has a 52-week low of $191.77 and a 52-week high of $335.86. The company has a 50-day moving average of $301.94 and a 200-day moving average of $286.54.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.